Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) is now available.
Lee’s Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical company, operates through subsidiaries including Zhaoke Hefei to invest in and develop life and health, biotechnology and related industries. The group leverages capital partnerships and strategic funds to support its core focus on innovative healthcare products and solutions.
The company announced that its indirect wholly owned subsidiary Zhaoke Hefei will commit RMB25 million to a new partnership fund managed by Ruifu Bojian, targeting unlisted life and health, biotechnology, and related upstream and downstream companies over an eight-year term. The investment constitutes a connected transaction under Hong Kong listing rules because the general partner is an associate of non-executive director Mr. Huang, but it falls within thresholds requiring only reporting and announcement, signalling continued strategic deployment of capital without necessitating shareholder approval.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical group engaged in the development, manufacture and marketing of drugs, with a focus on life and health-related therapeutics. Through subsidiaries such as Zhaoke Hefei, the company participates in strategic investments across biotechnology and associated upstream and downstream sectors to support its growth and innovation pipeline.
Average Trading Volume: 722,376
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$683M
See more insights into 0950 stock on TipRanks’ Stock Analysis page.